JP2009538276A5 - - Google Patents

Download PDF

Info

Publication number
JP2009538276A5
JP2009538276A5 JP2009507606A JP2009507606A JP2009538276A5 JP 2009538276 A5 JP2009538276 A5 JP 2009538276A5 JP 2009507606 A JP2009507606 A JP 2009507606A JP 2009507606 A JP2009507606 A JP 2009507606A JP 2009538276 A5 JP2009538276 A5 JP 2009538276A5
Authority
JP
Japan
Prior art keywords
deoxynojirimycin
pentane
neopentyloxy
methoxy
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2009507606A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009538276A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/NL2007/050177 external-priority patent/WO2007123403A1/en
Publication of JP2009538276A publication Critical patent/JP2009538276A/ja
Publication of JP2009538276A5 publication Critical patent/JP2009538276A5/ja
Ceased legal-status Critical Current

Links

JP2009507606A 2006-04-24 2007-04-24 嚢胞性線維症の改良型治療 Ceased JP2009538276A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79408806P 2006-04-24 2006-04-24
PCT/NL2007/050177 WO2007123403A1 (en) 2006-04-24 2007-04-24 Improved treatment of cystic fibrosis

Publications (2)

Publication Number Publication Date
JP2009538276A JP2009538276A (ja) 2009-11-05
JP2009538276A5 true JP2009538276A5 (enExample) 2010-04-08

Family

ID=38283020

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009507606A Ceased JP2009538276A (ja) 2006-04-24 2007-04-24 嚢胞性線維症の改良型治療

Country Status (10)

Country Link
US (1) US8410081B2 (enExample)
EP (1) EP2010551B1 (enExample)
JP (1) JP2009538276A (enExample)
CN (1) CN101479288B (enExample)
AT (1) ATE479696T1 (enExample)
AU (1) AU2007241622A1 (enExample)
BR (1) BRPI0710883A2 (enExample)
CA (1) CA2650311A1 (enExample)
DE (1) DE602007008870D1 (enExample)
WO (1) WO2007123403A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
EP2398321B1 (en) 2009-02-23 2015-11-25 United Therapeutics Corporation Iminosugars and methods of treating viral diseases
CA2753194A1 (en) * 2009-02-24 2010-09-02 United Therapeutics Corporation Iminosugars and methods of treating arenaviral infections
CN102639133B (zh) 2009-06-12 2015-03-11 联合治疗公司 亚氨基糖和治疗布尼亚病毒性疾病以及披膜病毒性疾病的方法
JP5752689B2 (ja) * 2009-09-04 2015-07-22 ユナイテッド セラピューティクス コーポレイション フィロウイルス疾患を治療するイミノ糖および方法
CA2772807A1 (en) * 2009-09-04 2011-03-10 The Chancellor, Masters And Scholars Of The University Of Oxford Methods of treating poxviral infections
US20110065752A1 (en) * 2009-09-04 2011-03-17 United Therapeutics Corporation Methods of treating orthomyxoviral infections
GB201000499D0 (en) 2010-01-13 2010-03-03 Fleet George W J Treatment of cystic fibrosis
WO2011095772A2 (en) 2010-02-04 2011-08-11 Summit Corporation Plc Novel iminosugar therapeutics
GB201006434D0 (en) 2010-04-19 2010-06-02 Summit Corp Plc Novel iminosugar combinations
ES2791760T3 (es) 2011-09-07 2020-11-05 Sinai School Medicine Ceramidasa y diferenciación celular
HUE051020T2 (hu) * 2012-06-01 2021-01-28 Icahn School Med Mount Sinai A ceramid szintjei a fertõzések kezelésében és megelõzésében
US20150346185A1 (en) * 2012-12-05 2015-12-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Diagnosis of cystic fibrosis
JP6832158B2 (ja) 2013-03-14 2021-02-24 アイカーン スクール オブ メディシン アット マウント サイナイ 治療用酸性セラミダーゼ組成物ならびにそれを作製および使用する方法
WO2017178499A1 (en) 2016-04-11 2017-10-19 Spedding Research Solutions Inhibitors of glucosylceramide degradation in the treatment of diseases of the motor units
MA48944A (fr) 2017-06-01 2020-04-08 Idorsia Pharmaceuticals Ltd Forme cristalline de n-butyldéoxygalactonojirimycine
CA3211755A1 (en) * 2021-03-12 2022-09-15 Barbara MERTINS Systems and methods for protein expression

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998002161A1 (en) 1996-07-15 1998-01-22 Universiteit Van Amsterdam Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors
WO2001002586A1 (en) 1999-06-29 2001-01-11 Mcgill University Human alpha 1,2-mannosidase
EP1528056A1 (en) * 2003-10-29 2005-05-04 Academisch Ziekenhuis bij de Universiteit van Amsterdam Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors
FR2861991B1 (fr) 2003-11-07 2008-01-18 Centre Nat Rech Scient Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
US20090111812A1 (en) * 2004-06-14 2009-04-30 Musc Foundation For Research Development Methods for treating inflammatory disorders
US20100004156A1 (en) 2005-07-27 2010-01-07 Shalesh Kaushal Small Compounds That Correct Protein Misfolding and Uses Thereof

Similar Documents

Publication Publication Date Title
JP2009538276A5 (enExample)
JP2004519469A5 (enExample)
JP2004538303A5 (enExample)
JP2011513196A5 (enExample)
JP2010504343A5 (enExample)
JP2007016035A5 (enExample)
JP2006526590A5 (enExample)
JP2009535370A5 (enExample)
JP2010502730A5 (enExample)
JP2010528011A5 (enExample)
JP2007514005A5 (enExample)
JP2009535307A5 (enExample)
JP2007501251A5 (enExample)
JP2007500154A5 (enExample)
JP2010511631A5 (enExample)
WO2009064374A8 (en) Oral formulations of bis(thiohydrazide amides)
JP2009500423A5 (enExample)
ES2489265T3 (es) Asociación de inhibidores de la HMG-CoA reductasa atorvastatina o simvastatina con un inhibidor de la fosfodiesterasa 4, tal como roflumilast para el tratamiento de enfermedades pulmonares inflamatorias
JP2008546770A5 (enExample)
JP2000159790A5 (enExample)
JP2008515980A5 (enExample)
RU2009119567A (ru) Уменьшение избыточной массы тела или ожирения
SE0401655D0 (sv) New compounds
JP2011068692A5 (enExample)
EA200500240A1 (ru) Новый способ синтеза соединений 1,3,4,5-тетрагидро-2h-3-бензазепин-2-она и применение при синтезе ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой